Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421533 · ClinicalTrials.gov registry record
Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke
A clinical trial, sponsored by Anthos Therapeutics.
- Terminated
- Registry status
- 705
- Enrollment target
NCT05421533: Clinical Trial study, sponsored by Anthos Therapeutics.
NCT05421533 is a clinical trial that was terminated before completion, run by Anthos Therapeutics. The registered enrollment target is 705 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05421533 was terminated before completion, sponsored by Anthos Therapeutics.
- TERMINATED
- Registry status
- 705 participants
- Enrollment target
Study Summary
The GARDENIA registry will collect real-world clinical data on the anticoagulant strategies in patients with AF at elevated risk of stroke but also elevated risk of bleeding.
Primary Outcome
Information collected from physicians will provide the clinical reasons for treatment or nontreatment with OACs as assessed by the treating physicians
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2024-09-30 |
Why NCT05421533 stopped before completion
NCT05421533 is an observational study that tracks outcomes without assigning an intervention. The registered 705 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05421533 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05421533 about?
NCT05421533 is a clinical study titled "Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke". The GARDENIA registry will collect real-world clinical data on the anticoagulant strategies in patients with AF at elevated risk of stroke but also elevated risk of bleeding.
What is the current status of trial NCT05421533?
This trial is currently terminated. The enrollment target is 705 participants. The study started on 2022-09-14. Estimated completion is 2024-09-30.
Who is sponsoring clinical trial NCT05421533?
This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI